Get the Stockscreener App
1.77
1.12%
-0.02
After Hours:
1.75
-0.02
-1.13%
InspireMD Inc. stock is traded at $1.77, with a volume of 15,882.
It is down -1.12% in the last 24 hours and down -2.75% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$1.79
Open:
$1.78
24h Volume:
15,882
Relative Volume:
0.43
Market Cap:
$75.00M
Revenue:
$8.98M
Net Income/Loss:
$-48.79M
P/E Ratio:
-2.2208
EPS:
-0.797
Net Cash Flow:
$-36.77M
1W Performance:
-1.12%
1M Performance:
-2.75%
6M Performance:
-25.32%
1Y Performance:
-35.40%
1-Day Range:
$1.75
$1.79
1-Week Range:
$1.67
$1.8999
52-Week Range:
$1.51
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
1.77 | 75.84M | 8.98M | -48.79M | -36.77M | -0.797 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Maxim Group | Buy |
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket trading - MSN
Geopolitics Watch: Can InspireMD Inc keep up with sector leadersMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
InspireMD Q2 2025 Earnings Preview - MSN
InspireMD targets $13M–$15M in 2026 revenue as CGuard Prime gains US traction - MSN
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Johnson & Johnson (JNJ) and InspireMD (NSPR) - The Globe and Mail
InspireMD, Inc. (NSPR) reports Q4 loss, beats revenue estimates - MSN
InspireMD revenue up 62% to USD 3.1M in Q4 2025 - Medical Buyer
Returns Recap: Can InspireMD Inc outperform in the next rallyDay Trade & Safe Entry Trade Reports - baoquankhu1.vn
InspireMD’s Growth Hinges on Real CAS Market Size and Physician Adoption - TipRanks
InspireMD Reports 62% Q4 Revenue Growth and Sets 2026 Outlook for CGuard Prime Carotid Stent System - Minichart
Earnings call transcript: InspireMD Q4 2025: Revenue Surges, EPS Beats By Investing.com - Investing.com South Africa
InspireMD earnings beat by $0.05, revenue topped estimates - Investing.com Canada
InspireMD, Inc. (NSPR) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
InspireMD Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: InspireMD Q4 2025: Revenue Surges, EPS Beats - Investing.com
InspireMD, Inc. Overview: CGuard Carotid Stent Technology, Business Strategy, and Market Leadership in Stroke Prevention 72 - Minichart
InspireMD Reports Strong Q4 2025 Growth and Expansion - TipRanks
FDA PMA and global expansion reshape InspireMD (NSPR) carotid focus - Stock Titan
InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
InspireMD, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
InspireMD Q4 net income USD -11.761 million - marketscreener.com
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
INSPIREMD ($NSPR) Releases Q4 2025 Earnings - Quiver Quantitative
InspireMD (NSPR) revenue climbs 28% in 2025 as net loss widens - Stock Titan
InspireMD Q4 revenue rises 62%, beats estimates - TradingView
NSPR: Q4 2025 revenue surged 62% year-over-year, with 2026 revenue growth projected at up to 65% - TradingView
Stroke stent maker InspireMD lifts sales 62% and targets up to $15M in 2026 - Stock Titan
InspireMD, Inc. (NSPR) Announces Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
InspireMD Q4 2025 earnings preview - MSN
InspireMD, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
921,587 Shares in InspireMD, Inc. $NSPR Purchased by Ghisallo Capital Management LLC - MarketBeat
Stock Recap: Is InspireMD Inc a momentum stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
Rosalind Advisors Inc. Purchases 1,616,644 Shares of InspireMD, Inc. $NSPR - MarketBeat
InspireMD (NSPR) price target increased by 25.00% to 5.10 - MSN
Aug Opening: Can InspireMD Inc outperform in the next rally2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
Aug PreEarnings: Is InspireMD Inc stock risky to hold now2026 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
InspireMD, Inc. Scheduled to Release Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 - Quiver Quantitative
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Carotid stent developer InspireMD sets March 18 results call - Stock Titan
InspireMD (NSPR) price target decreased by 11.11% to 4.08 - MSN
Is InspireMD Inc. stock dividend yield sustainableWeekly Risk Report & Verified Momentum Watchlists - Naître et grandir
InspireMD Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
InspireMD announces dismissal of chief operating officer Andrea Tommasoli By Investing.com - Investing.com Australia
InspireMD Announces Planned Departure of Chief Operating Officer - TipRanks
InspireMD announces dismissal of chief operating officer Andrea Tommasoli - Investing.com
Embolic Protection Devices Market to Reach USD 1,161.31 Million by 2032, Growing at a CAGR of 7.58% | DelveInsight - Barchart.com
InspireMD dismisses COO Andrea Tommasoli; last day expected Sept 1, 2026 - TradingView
InspireMD (NSPR) outlines COO dismissal, French-law notice and €61k severance - Stock Titan
InspireMD, Inc. Announces Dismissal of Chief Operating Officer Andrea Tommasoli, Effective April 1, 2026 - marketscreener.com
Tangible book value per share of InspireMD Inc. – LSX:A3CMP3 - TradingView
NSPR Technical Analysis & ETF Price Forecast - Intellectia AI
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):